Luye, Elpis collaborate on dual-targeting CAR Ts

Luye Pharma Group Ltd. (HKSE:2186) and Elpis Biopharmaceuticals Corp. (Mass.) partnered to discover and develop dual-targeting CAR T therapies. Luye declined to disclose specific targets.

Elpis will use its antibody discovery and development platforms to generate candidates prespecified by the partners. The company will have exclusive rights outside of China...